IRCT20090117001556N113RecruitingPhase 3
Effect of propentofylline add on therapy to risperidon in children with autism: a randomized double-blind placebo-controlled clinical trial
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 4 years to 11 years (—)
- Sex
- All
Inclusion Criteria
- •DSM-5 clinical diagnosis of autistic disorder
- •Children between the ages of 4 and 11 years old
- •score 12 or more inirritability subscale of ABC-C
Exclusion Criteria
- •Presence of any active medical problem
- •Receiving any psychotropic medications except for risperidone during 2 weeks prior to the trial
- •Severe hepatic disease
- •History of allergy to risperidone and intolerance of it
- •History of seizure requiring change of antiepileptic dose during the last month
- •Seizure during the last 6 months
Investigators
Similar Trials
Recruiting
Phase 2
The effect of pentoxifylline in the treatment of Covid-19 diseaseIRCT20110425006280N11Vice President of Research Guilan university of medical sciences20
Not yet recruiting
Phase 3
Investigation of the effect of pentoxifylline on Covid-19IRCT20170609034406N8Tabriz University of Medical Sciences100
Completed
Phase 3
Effect of Pentoxifylline in the treatment of chronic venous ulcerschronic venous ulcers.Varicose veins of lower extremities with ulcerIRCT201012085344N1Shahrood University of Medical Sciences and Health Services40
Completed
Early Phase 1
Pretreatment pentoxifylline and control of post operative paiIRCT20180522039773N1Sabzevar University of Medical Sciences90
Not yet recruiting
Phase 1
A study combining blood pressure medication with standard treatment in advanced melanoma. ACE-IT-001Melanoma - UnresectableMelanoma - MetastaticCancer - Malignant melanomaACTRN12621000156886Calvary Mater Newcastle30